PAVmed (PAVM) EBITDA (2016 - 2025)

PAVmed's EBITDA history runs 10 years deep, the most recent figure standing at -$6.8 million for Q4 2025.

• On a quarterly basis, EBITDA fell 31.15% year-over-year to -$6.8 million in Q4 2025; TTM through Dec 2025 was -$21.8 million, a 55.76% increase from a year earlier, with the FY2025 full-year figure at -$21.8 million, up 50.98% from the prior year.
• EBITDA declined to -$6.8 million in Q4 2025 per PAVM's latest filing, from -$4.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.7 million in Q2 2025 and bottomed at -$24.6 million in Q4 2022.
• The 5-year median for EBITDA is -$14.0 million (2024), against an average of -$14.2 million.
• Across the five-year window, EBITDA tumbled 160.44% in 2021 and jumped 68.34% in 2024, its largest moves.
• Year by year, EBITDA stood at -$19.7 million in 2021, then declined by 25.01% to -$24.6 million in 2022, then soared by 33.41% to -$16.4 million in 2023, then soared by 68.34% to -$5.2 million in 2024, then tumbled by 31.15% to -$6.8 million in 2025.
• Per Business Quant, the three latest PAVM EBITDA figures stand at -$6.8 million (Q4 2025), -$4.8 million (Q3 2025), and -$4.7 million (Q2 2025).